Since the early 2000s cardiac biomarkers have become the cornerstone for diagnosis, risk stratification and therapeutic decision in cardiovascular diseases, specifically NT-proBNP (congestive heart failure) and cardiac troponins (acute coronary syndromes).
coronary artery disease (CAD)
N Terminal-pro Brain Natriuretic Peptide (NT-pro BNP) is produced by cardiac muscle cells (myocytes) in response to cardiac wall stress and myocardial ischemia. NT-pro BNP has been shown to predict all-cause mortality in insurance applicants without a history of heart disease, as well as in the general population. It has been found to improve future cardiovascular risk estimation when considered along with classic cardiovascular risk assessors. It has also been identified as an indicator of future mortality risk in those having stable coronary atherosclerotic heart disease (CAD)
Presentations from the 2016 Wisconsin Association of Health and Life Underwriters (WAHLU) Spring Seminar have been posted at their website. Presentations include:
- CAD and Beyond
- Neuropsychology and Cognitive Disorders